AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18370567 — intervention group
Group type: COMPARATOR
Intervention: No HMG-CoA reductase inhibitor (statin) therapy
Number of subjects: 0
Study 16319510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GMC) 1,200 mg/m² on days 1 and 8, Cisplatin (CDDP) 75 mg/m² on day 2, repeated every 21 days
Number of subjects: 27
Study 16319510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GMC) and Cisplatin (CDDP) regimen
Number of subjects: 27
Study 11752997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine (2 mg)
Number of subjects: 65
Study 11752997 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 65
Study 10079447 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 105
Study 10079447 — intervention group
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Number of subjects: 105
Study 10079447 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac
Number of subjects: 105
Study 10079447 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone acetate
Number of subjects: 105
Study 10079447 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 7484027 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1
Number of subjects: 30
Study 7484027 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms kg‐1
Number of subjects: 30
Study 7484027 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1 mg kg‐1 without prior atracurium or anticholinesterase administration
Number of subjects: 30
Study 2387660 — intervention group
Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine
Number of subjects: 12
Study 2387660 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6113021 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g sulphasalazine retention enemas
Number of subjects: 34
Study 6113021 — intervention group
Group type: COMPARATOR
Intervention: Placebo retention enemas
Number of subjects: 34
Study 31936621 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 140 mL
Number of subjects: 10
Study 31936621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 31683114 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological First Aid training (60 min sessions, once a week for 6 weeks)
Number of subjects: 76
Study 27942868 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Music Therapy Group (EMG)
Number of subjects: 100
Study 25979840 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions
Number of subjects: 6
Study 25979840 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic contractions
Number of subjects: 6
Study 23274144 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC capsule containing lamivudine/adefovir dipivoxil 100/10 mg
Number of subjects: 40
Study 23274144 — intervention group
Group type: COMPARATOR
Intervention: Conventional lamivudine 100 mg + adefovir dipivoxil 10 mg tablets
Number of subjects: 40
Study 23274144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (FDC and conventional tablets)
Number of subjects: 40
Study 21113613 — intervention group
Group type: EXPERIMENTAL
Intervention: Poling frequency of 40 cycles·min(‐1) (Pf(40))
Number of subjects: 9
Study 21113613 — intervention group
Group type: EXPERIMENTAL
Intervention: Poling frequency of 60 cycles·min(‐1) (Pf(60))
Number of subjects: 9
Study 21113613 — intervention group
Group type: EXPERIMENTAL
Intervention: Poling frequency of 80 cycles·min(‐1) (Pf(80))
Number of subjects: 9
Study 21113613 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Pf(40), Pf(60), and Pf(80)
Number of subjects: 9
Study 22642735 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treatment
Number of subjects: 29
Study 22642735 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based treatment
Number of subjects: 29
Study 22642735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 29
Study 16817045 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medical treatment
Number of subjects: 139
Study 12753488 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy training group (HT, n = 10)
Number of subjects: 17
Study 12753488 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 17
Study 10680924 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Number of subjects: 62
Study 10680924 — intervention group
Group type: COMPARATOR
Intervention: Otic drops
Number of subjects: 62
Study 9058223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.15 mg/kg
Number of subjects: 20
Study 9058223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.2 mg/kg
Number of subjects: 20
Study 9058223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (both doses)
Number of subjects: 20
Study 8342319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent cold recombinant type A (CRA) vaccines
Number of subjects: 52
Study 8342319 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza (TI) vaccines
Number of subjects: 52
Study 8342319 — intervention group
Group type: COMPARATOR
Intervention: Normal saline by nose drops (Pli.n.)
Number of subjects: 52
Study 8342319 — intervention group
Group type: COMPARATOR
Intervention: Normal saline intramuscularly (Pli.m.)
Number of subjects: 52
Study 3578940 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transfusion (group II)
Number of subjects: 160
Study 3578940 — intervention group
Group type: COMPARATOR
Intervention: Control group (group I)
Number of subjects: 160
Study 3578940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 29661635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving intermittent preventive treatment (IPT) with dihydroartemisinin-piperaquine (DP)
Number of subjects: 10079
Study 29661635 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 10079
Study 29661635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving IPT with DP
Number of subjects: 10079
Study 28071624 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated RT (six fractions per week, Monday-Saturday)
Number of subjects: 60
Study 28071624 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT (five fractions per week, Monday-Friday)
Number of subjects: 60
Study 28071624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Accelerated RT and Conventional RT)
Number of subjects: 60
Study 24702445 — intervention group
Group type: EXPERIMENTAL
Intervention: o/w formulation containing licochalcone A, decanediol, menthoxypropanediol and ω‐6‐fatty acids (emollient arm)
Number of subjects: 20
Study 24702445 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone (HC arm)
Number of subjects: 20
Study 23984793 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide + Metformin
Number of subjects: 174
Study 23984793 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Metformin
Number of subjects: 174
Study 20530557 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and home exercise programme
Number of subjects: 120
Study 20530557 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (inactive ultrasound therapy and inert gel)
Number of subjects: 120
Study 18206891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hcy-lowering agents (folate 1000 mcg, vitamin B12 400 mcg, vitamin B6 10 mg)
Number of subjects: 60
Study 18206891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16447306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program (6-month group-based)
Number of subjects: 134
Study 16447306 — intervention group
Group type: COMPARATOR
Intervention: Educational Support Program (group-based)
Number of subjects: 134
Study 16447306 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Program (no group)
Number of subjects: 134
Study 16447306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 134
Study 15531493 — intervention group
Group type: COMPARATOR
Intervention: 10 x 250 mg T enanthate (TE) im every 3 wk (n = 20)
Number of subjects: 40
Study 15531493 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 1000 mg TU im every 6 wk (loading dose) followed by 1 x 1000 mg after an additional 9 wk (n = 20)
Number of subjects: 40
Study 15531493 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 x 1000 mg TU every 12 wk in former TU patients (n = 20)
Number of subjects: 40
Study 15531493 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 1000 mg TU every 8 wk plus 6 x 1000 mg every 12 wk in former TE patients (n = 16)
Number of subjects: 40
Study 11570643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment
Number of subjects: 40
Study 11570643 — intervention group
Group type: COMPARATOR
Intervention: Control (no DEX treatment)
Number of subjects: 40
Study 9663150 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-site wellness-health program interventions
Number of subjects: 0
Study 9663150 — intervention group
Group type: COMPARATOR
Intervention: Control group (workers from two other sites)
Number of subjects: 0
Study 8173679 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 8173679 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study 3223457 — intervention group
Group type: EXPERIMENTAL
Intervention: 6,000 micrograms/day mecobalamin
Number of subjects: 375
Study 3223457 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 micrograms/day mecobalamin
Number of subjects: 375
Study 3223457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 29413802 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback during rehabilitation
Number of subjects: 24
Study 29413802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 24
Study 29413802 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback
Number of subjects: 24
Study 28269765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab IV
Number of subjects: 2452
Study 28269765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2452
Study 25658816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 18
Study 25658816 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 25658816 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 18
Study 25658816 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 18
Study 23484826 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 283
Study 23484826 — intervention group
Group type: COMPARATOR
Intervention: Prolonged conservative care
Number of subjects: 283
Study 23484826 — intervention group
Group type: EXPERIMENTAL
Intervention: Disk herniation visible
Number of subjects: 283
Study 23484826 — intervention group
Group type: EXPERIMENTAL
Intervention: No disk herniation
Number of subjects: 283
Study 23484826 — intervention group
Group type: EXPERIMENTAL
Intervention: Disk herniation
Number of subjects: 283
Study 23484826 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment
Number of subjects: 283
Study 21419556 — intervention group
Group type: EXPERIMENTAL
Intervention: SNIP
Number of subjects: 52
Study 21419556 — intervention group
Group type: EXPERIMENTAL
Intervention: PImax
Number of subjects: 52
Study 21419556 — intervention group
Group type: COMPARATOR
Intervention: Pes (reference variable)
Number of subjects: 52
Study 18815989 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-administered interventions
Number of subjects: 0
Study 18815989 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16946607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gums (1.3 g xylitol)
Number of subjects: 12
Study 16946607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucking tablets (0.8 g xylitol)
Number of subjects: 12
Study 16946607 — intervention group
Group type: EXPERIMENTAL
Intervention: Candy tablets (1.1 g xylitol)
Number of subjects: 12
Study 16946607 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste (0.1 g xylitol)
Number of subjects: 12
Study 16946607 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse (1.0 g xylitol)
Number of subjects: 12
Study 16946607 — intervention group
Group type: EXPERIMENTAL
Intervention: LX rinse (2.0 g xylitol)
Number of subjects: 12
Study 16946607 — intervention group
Group type: EXPERIMENTAL
Intervention: HX rinse (6.0 g xylitol)
Number of subjects: 12
Study 16946607 — intervention group
Group type: COMPARATOR
Intervention: Control (non‐xylitol paraffin)
Number of subjects: 12
Study 14512708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abusers
Number of subjects: 0
Study 14512708 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 11195958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum extractor
Number of subjects: 210
Study 11195958 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 210
Study 11195958 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 9187688 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4222
Study 9187688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4222
Study 8416021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal arginine vasopressin (20 IU)
Number of subjects: 43
Study 8416021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU)
Number of subjects: 43
Study 8416021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3753116 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training
Number of subjects: 65
Study 3753116 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor education
Number of subjects: 65
Study 3753116 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 29247670 — intervention group
Group type: EXPERIMENTAL
Intervention: High heat capacity mattress (HHCM)
Number of subjects: 15
Study 27508910 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on the sanyinjiao point for 20 minutes during contractions
Number of subjects: 156
Study 27508910 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 156
Study 27508910 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 24287402 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment via GPs (N = 144)
Number of subjects: 832
Study 24287402 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment via newspapers (N = 213)
Number of subjects: 832
Study 24287402 — intervention group
Group type: COMPARATOR
Intervention: Recruitment via GPs
Number of subjects: 832
Study 22933207 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial treatment (TT)
Number of subjects: 189
Study 22933207 — intervention group
Group type: COMPARATOR
Intervention: Routine thrombolytic treatment (Thrx)
Number of subjects: 189
Study 22933207 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial treatment (TT) subgroup (refused participation)
Number of subjects: 189
Study 20424804 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement intervention (oral liquid nutrition supplementation)
Number of subjects: 63
Study 20424804 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-meal snacks intervention
Number of subjects: 63
Study 20424804 — intervention group
Group type: COMPARATOR
Intervention: Usual NH care control
Number of subjects: 63
Study 18519918 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg qd for 14 days
Number of subjects: 0
Study 18519918 — intervention group
Group type: EXPERIMENTAL
Intervention: carbamazepine titrated to 400 mg qd for 21 days
Number of subjects: 0
Study 18519918 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of carbamazepine with efavirenz
Number of subjects: 0
Study 15988694 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone (D)
Number of subjects: 33
Study 15988694 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone (EX)
Number of subjects: 33
Study 15988694 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise (D + E)
Number of subjects: 33
Study 15988694 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 33
Study 12550149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises
Number of subjects: 0
Study 12550149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 0
Study 12550149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10539093 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal immunomodulator (Esberitox N)
Number of subjects: 0
Study 10539093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8905957 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium sized probe
Number of subjects: 6
Study 8905957 — intervention group
Group type: COMPARATOR
Intervention: Adult type probe
Number of subjects: 6
Study 8905957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both probes
Number of subjects: 6
Study 1660530 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (28 g [1 oz] twice daily)
Number of subjects: 145
Study 1660530 — intervention group
Group type: COMPARATOR
Intervention: Wheat cereal
Number of subjects: 145
Study 1660530 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (AHA-I diet)
Number of subjects: 145
Study 10328017 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ; 80 mg of TMP and 400 mg of SMZ per tablet; nine tablets taken once daily for three days; total, 27 tablets)
Number of subjects: 938
Study 10328017 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (2 g daily for five days)
Number of subjects: 938
Study 10328017 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 938
Study 30673547 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (by pipelle biopsy)
Number of subjects: 1364
Study 30673547 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1364
Study 30673547 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Number of subjects: 1364
Study 30246016 — intervention group
Group type: EXPERIMENTAL
Intervention: Huaier (combined with sugar-free Yinxie granules and Huaiqihuang granules)
Number of subjects: 0
Study 30246016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (combined with sugar-free Yinxie granules)
Number of subjects: 0
Study 26456162 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.5%) cream
Number of subjects: 50
Study 26456162 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (2%) cream
Number of subjects: 50
Study 24745802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet applied directly to the skin
Number of subjects: 97
Study 22061340 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based intervention
Number of subjects: 1275
Study 22061340 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based intervention
Number of subjects: 1275
Study 22061340 — intervention group
Group type: COMPARATOR
Intervention: Parent and peer conditions
Number of subjects: 1275
Study 18848480 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS HOTV visual acuity protocol
Number of subjects: 142
Study 18848480 — intervention group
Group type: COMPARATOR
Intervention: E-ETDRS visual acuity protocol
Number of subjects: 142
Study 18161613 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of key methodological items in RCTs
Number of subjects: 67
Study 15896919 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine challenge study for assessment of growth hormone release as a marker of tonic noradrenergic activation.
Number of subjects: 90
Study 15896919 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 90
Study 12059915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel‐titanium rotary instruments with additional apical enlargement to ISO size 35 (Group A, n = 16)
Number of subjects: 38
Study 12059915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel‐titanium rotary instruments with no apical enlargement (Group B, n = 16)
Number of subjects: 38
Study 12059915 — intervention group
Group type: COMPARATOR
Intervention: Control group with irrigation only (Group C, n = 6)
Number of subjects: 38
Study 11167902 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 11167902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8923354 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB 486IL-2 at 0.075 mg/kg/day
Number of subjects: 22
Study 8923354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 22
Study 1442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 24
Study 1442480 — intervention group
Group type: COMPARATOR
Intervention: Single‐photon emission computed tomography (SPECT) thallium‐201 exercise scintigraphy
Number of subjects: 24
Study 2578367 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm bath (HOT)
Number of subjects: 6
Study 2578367 — intervention group
Group type: COMPARATOR
Intervention: Cool bath (COOL)
Number of subjects: 6
Study 31368031 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program 3 days/week for 3 months (Group A)
Number of subjects: 25
Study 31368031 — intervention group
Group type: COMPARATOR
Intervention: Exercise-free (Group B)
Number of subjects: 25
Study 31368031 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (Group C)
Number of subjects: 25
Study 30145664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 30
Study 30145664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30